Gyre director granted 40,000 stock options
GYRE THERAPEUTICS, INC. director Renate Parry received a grant of stock options covering 40,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. director Renate Parry received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036. According to the disclosure, the award vests in 12 equal monthly installments through June 10, 2027, contingent on Parry’s continued service to the company. This is a compensation-related acquisition, with no open‑market buying or selling reported in this filing.
Insider Trade Summary
Grant/Award: 40,000 shares
Grant/Award
1 txn
Insider
Parry Renate
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 40,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 contracts (Direct)
Footnotes (1)
- F1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Key Figures
Option grant size: 40,000 options
Exercise price: $5.95 per share
Underlying shares: 40,000 shares
+3 more
6 metrics
Option grant size
40,000 options
Stock Option (Right to Buy) granted June 10, 2026
Exercise price
$5.95 per share
Exercise price of stock option grant
Underlying shares
40,000 shares
Common stock underlying the options
Post-grant derivative holdings
40,000 options
Total options following transaction for this award
Expiration date
June 10, 2036
Option expiry for this grant
Vesting period end
June 10, 2027
Final vesting date; 12 equal monthly installments
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for the reported transaction"
exercise price financial
"conversion_or_exercise_price of 5.9500 indicates the option exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"options "will vest in 12 equal monthly installments through June 10, 2027""
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-10" for the stock option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did GYRE director Renate Parry report on this Form 4?
Renate Parry reported receiving a stock option grant for 40,000 shares of Gyre Therapeutics common stock. The award is a compensation-related acquisition, not an open-market trade, and gives the right to buy shares at a fixed exercise price.
What is the exercise price of Renate Parry’s GYRE stock options?
The stock options granted to Renate Parry have an exercise price of $5.95 per share. This is the price at which she can purchase Gyre Therapeutics common stock once the options vest and are exercisable, subject to the award’s terms.
How do Renate Parry’s GYRE stock options vest over time?
The 40,000 Gyre Therapeutics stock options vest in 12 equal monthly installments through June 10, 2027. Vesting is conditioned on Parry’s continued service to the company on each monthly vesting date during this period.
When do Renate Parry’s GYRE stock options expire?
The stock options granted to Renate Parry expire on June 10, 2036. After that expiration date, any unexercised options will lapse, and the right to purchase Gyre Therapeutics common stock under this grant will end.
Does this GYRE Form 4 show any open-market stock purchases or sales?
This Form 4 does not report any open-market purchases or sales of Gyre Therapeutics stock. It discloses only a compensation-related stock option grant to director Renate Parry, classified as a grant, award, or other acquisition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates